Poor
Not Aligned
Patient Risk:
High
Summary
Several quantitative liver-enzyme incidence claims are misstated/contradicted, and multiple hepatitis C/DAA-specific interaction and monitoring claims are not supported by the provided Lipitor label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) carries a risk of liver injury.
Supported by 5.2 Liver Dysfunction (statins associated with liver function biochemical abnormalities; transaminase elevations).
Increased atorvastatin levels raise the risk of muscle toxicity.
Supported by 7.1 Strong Inhibitors of CYP 3A4 (increases in plasma concentrations) and 5.1 Skeletal Muscle (myopathy/rhabdomyolysis risk).
Unsupported Statements
The statin class interacts with hepatitis C treatments.
No hepatitis C/DAA interactions are mentioned in the provided label excerpts.
Direct-acting antivirals such as sofosbuvir can raise atorvastatin levels.
Not supported in the provided drug-interaction excerpts (no sofosbuvir/DAA combinations).
Direct-acting antivirals such as ledipasvir can raise atorvastatin levels.
Not supported in the provided drug-interaction excerpts (no ledipasvir/DAA combinations).
Increased atorvastatin levels raise the risk of liver toxicity.
Label excerpts discuss liver enzyme abnormalities and monitoring, but do not state that increased atorvastatin levels (per se) increase liver toxicity as claimed.
The FDA recommends dose adjustments or alternative statins when using atorvastatin with these antiviral combinations.
Provided interaction guidance concerns specific strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, itraconazole) and includes cautions on atorvastatin doses; no hepatitis C antiviral combinations or alternative-statin instruction is present in the provided excerpts.
Monitoring liver enzymes is essential when using Lipitor in hepatitis C patients.
Label excerpts recommend LFTs prior to and at 12 weeks and periodically, but do not mention hepatitis C patients specifically.
Lipitor's primary compound patent expired years ago.
Not a prescribing-information statement in the provided label sections.
Generics dominate the atorvastatin market today.
Not present in the provided prescribing-information sections.
Contradictions
High
AI Statement
The FDA label for Lipitor warns that transaminase elevations occur in 0.7% of patients receiving 10 mg.
Label Reference
5.2 Liver Dysfunction
Important Omissions
For liver monitoring, the label states LFTs should be performed prior to and at 12 weeks following initiation and after any elevation of dose, and periodically thereafter, and recommends dose reduction/withdrawal if ALT/AST >3x ULN persists (not necessarily a 6–12 week window or 'must' wording).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Hepatitis C/DAA-specific interaction claims and monitoring/dosing modification claims are not supported by the provided FDA label excerpts, and a numerical incidence claim is contradicted. These issues could mislead clinical decision-making relative to the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple hepatitis C/DAA-specific statements and several imprecise/incorrect liver monitoring and incidence figures are not supported by the provided label excerpts; one incidence statement is contradicted.
Suggested Improvement
Restrict claims to the provided label language: (1) use the label-supported transaminase incidence definitions and dose-specific rates from 5.2; (2) avoid naming hepatitis C drugs (e.g., sofosbuvir/ledipasvir) unless present in the label excerpt; (3) use the label’s LFT timing (prior to and at 12 weeks after initiation and after dose increases) and threshold-based language for ALT/AST >3x ULN with persistence.